Robert J de Knegt (Robert De Knegt, Robert de Knegt)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 28

Top Topics

Community Dwelling

Mild Cognitive Impairment

Top Venues

Hepatology (Baltimore, Md.)

Alimentary pharmacology & therapeutics

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

Laurens A van Kleef, Tian Xiao, Robert J de Knegt, M Arfan Ikram
Author Response: Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. Neurology 100 (2) (2023)
Laurens A van Kleef, Tian Xiao, Robert J de Knegt, M Arfan Ikram
Author Response: Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. Neurology 100 (2) (2023)
Laurens A van Kleef, Robert J de Knegt, Ibrahim Ayada, Maikel P Peppelenbosch, Willem Pieter Brouwer
The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population. Hepatology communications 7 (4) (2023)
Marleen van Dijk, Anders Boyd, Sylvia M Brakenhoff, Cas J Isfordink, Rosan A van Zoest, Mark D Verhagen, Robert J de Knegt, Joost Paulus Hubertus Drenth, Marc van der Valk, null null
Socio-economic factors associated with loss to follow-up among individuals with HCV: A Dutch nationwide cross-sectional study. Liver international : official journal of the International Association for the Study of the Liver (2023)
Laurens A van Kleef, Robert J de Knegt, Willem Pieter Brouwer
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Milan J Sonneveld, Maryam Kavousi, M Arfan Ikram, Robert A de Man, Robert J de Knegt
Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Robert J de Knegt, Willem Pieter Brouwer
Reply. Hepatology (Baltimore, Md.) (2022)
C Louwrens Braal, Robert J de Knegt, Agnes Jager, Stijn L W Koolen, Ron H J Mathijssen, Karel Eechoute
Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. Hepatology communications 6 (9) (2022)
Sem J Aronson, Norman Junge, Mediha Trabelsi, Wided Kelmemi, Aurelie Hubert, Karlla W Brigatti, Michael D Fox, Robert J de Knegt, Johanna C Escher, Virginia M Ginocchio, Raffaele Iorio, Yan Zhu, Figen Özçay, Fakher Rahim, Mortada H F El-Shabrawi, Eyal Shteyer, Angelo Di Giorgio, Lorenzo D'Antiga, Federico Mingozzi, Nicola Brunetti-Pierri, Kevin A Strauss, Philippe Labrune, Ridha Mrad, Ulrich Baumann, Ulrich H W Beuers, Piter J Bosma, null null
Disease burden and management of Crigler-Najjar syndrome: Report of a world registry. Liver international : official journal of the International Association for the Study of the Liver 42 (7) (2022)
Laurens A van Kleef, Robert J de Knegt
Modifiable risk factors for fatty liver disease: Time to act. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Robert J de Knegt, Willem Pieter Brouwer
Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Robert J de Knegt
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". Hepatology communications 6 (9) (2022)
Tian Xiao, Laurens A van Kleef, M Kamran Ikram, Robert J de Knegt, Mohammad Arfan Ikram
Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. Neurology 99 (6) (2022)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Robert J de Knegt
The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? Hepatology (Baltimore, Md.) 76 (5) (2022)
Pere Ginès, Laurent Castera, Frank Lammert, Isabel Graupera, Miquel Serra-Burriel, Alina M Allen, Vincent Wai-Sun Wong, Phillipp Hartmann, Maja Thiele, Llorenç Caballeria, Robert J de Knegt, Ivica Grgurevic, Salvador Augustin, Emmanuel A Tsochatzis, Jörn Markus Schattenberg, Indra Neil Guha, Andrea Martini, Rosa M Morillas, Montserrat Garcia-Retortillo, Harry de Koning, Núria Fabrellas Padrés, Judit Pich, Ann T Ma, M Alba Diaz, Dominique Roulot, Philip Noel Newsome, Michael Manns, Patrick S Kamath, Aleksander Krag, null null
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology (Baltimore, Md.) (2021)
Sylvia M Brakenhoff, Robert A de Man, Robert J de Knegt, Harry L A Janssen, Milan J Sonneveld
Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response. Authors' reply. Alimentary pharmacology & therapeutics 53 (4) (2021)
Louise Johanna Maria Alferink, Djawad Radjabzadeh, Nicole Stephanie Erler, Dina Vojinovic, Carolina Medina-Gomez, André G Uitterlinden, Robert J de Knegt, Najaf Amin, M Arfan Ikram, Harry L A Janssen, Jessica C Kiefte-de Jong, Herold J Metselaar, Cornelia M van Duijn, Robert Kraaij, Sarwa Darwish Murad
Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. Hepatology (Baltimore, Md.) 73 (3) (2021)
Laurens A van Kleef, Ibrahim Ayada, Louise Johanna Maria Alferink, Maikel P Peppelenbosch, Robert J de Knegt
Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study. Hepatology (Baltimore, Md.) (2021)
Aafke A Duizendstra, Robert J de Knegt, Shanta Mancham, Mariska Klepper, Dave L Roelen, Simone H Brand-Schaaf, Patrick P Boor, Michail Doukas, Robert A de Man, Dave Sprengers, Maikel P Peppelenbosch, Michiel G H Betjes, Jaap Kwekkeboom, Nicolle H R Litjens
Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021)
Marleen van Dijk, Sylvia M Brakenhoff, Cas J Isfordink, Wei-Han Cheng, Hans Blokzijl, Greet Boland, Anthonius S M Dofferhoff, Bart van Hoek, Daniel Johannes Touw, Milan J Sonneveld, Marc van der Valk, Joost P H Drenth, Robert J de Knegt
The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. Journal of clinical medicine 10 (19) (2021)
Sylvia M Brakenhoff, Robert A de Man, André Boonstra, Margo J H van Campenhout, Robert J de Knegt, Florian van Bömmel, Annemiek A van der Eijk, Thomas Berg, Bettina E Hansen, Harry L A Janssen, Milan J Sonneveld
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Alimentary pharmacology & therapeutics 53 (2) (2020)
Milan J Sonneveld, Willem Pieter Brouwer, Bettina E Hansen, Henry Lik Yuen Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Rong-Nan Chien, Hannah Choi, Robert J de Knegt, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Maria Buti Ferret, Robert A de Man, Harry L A Janssen, null null
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Alimentary pharmacology & therapeutics 52 (8) (2020)
Xiaofang Zhang, Michelle M J Mens, Yasir J Abozaid, Daniel Bos, Sarwa Darwish Murad, Robert J de Knegt, M Arfan Ikram, Maikel P Peppelenbosch, Mohsen Ghanbari
Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary pharmacology & therapeutics 53 (3) (2020)
Jose D Debes, Andre Boonstra, Robert J de Knegt
NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse. Hepatology (Baltimore, Md.) 71 (3) (2020)
Milan J Sonneveld, Robert J de Knegt
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Alimentary pharmacology & therapeutics 51 (1) (2020)